Heart transplantation from donation after circulatory death donors: Present and future
AbstractThe first successful human heart transplantation was reported on 3 December 1967, by Christiaan Barnard in South Africa. Since then this life ‐saving procedure has been performed in over 120 000 patients. A limitation to the performance of this procedure is the availability of donor hearts with as many as 20% of patients dying before a donor's heart is available for transplant. Today, hearts for transplantation are procured from indiv iduals experiencing donation after brain death (DBD). Interestingly, this, however, was not always the case as the first heart transplants occurred after circulatory death. Revisiting the availability of hearts for transplant from those experiencing donation after circulatory death (DCD) could fur ther expand the number of hearts suitable for transplantation. There are several considerations pertinent to transplanting hearts from those undergoing circulatory death. In this review, we summarize the main distinctions between DBD and DCD heart donation and discuss the research relevant to increa sing the number of hearts available for transplantation by including individual's hearts that experience circulatory death.
Publication date: Available online 9 October 2020Source: Revista Española de Cardiología (English Edition)Author(s): Francisco González-Vilchez, Luis Almenar-Bonet, María G. Crespo-Leiro, Manuel Gómez-Bueno, José González-Costello, Félix Pérez-Villa, Juan Delgado-Jiménez, José María Arizón del Prado, José Manuel Sobrino-Márquez, Iago Sousa Casasnovas, on behalf of the Spanish Heart Transplant Teams, Collaborators in the Spanish Heart Transplant Registry, 1984-2019, Javier Segovia-Cubero, Francisco Hernández-P&eac...
Publication date: Available online 8 October 2020Source: The Annals of Thoracic SurgeryAuthor(s): John P. Scott, William S. Ragalie, Karl D. Stamm, Donna K. Mahnke, Huan ling Liang, Pippa M. Simpson, Mahua Dasgupta, Ronit Katz, Paula E. North, Aoy Tomita-Mitchell, Steven D. Zangwill, Steven J. Kindel, Michael E. Mitchell
If considering a heart transplant or have a loved one who needs one, here are some things to know about getting an organ and other advances in transplant.
AbstractBackground and objective The main objective was to evaluate the impact of Hepatitis C Virus treatment with direct-acting antiviral agents on tacrolimus blood levels in recipients of kidney and heart allografts.Method We analysed Hepatitis C Virus infected adult patients who received tacrolimus as immunosuppressive maintenance therapy and received direct-acting antiviral agents treatment in a tertiary hospital with solid transplant multidisciplinary program in Madrid, Spain. Liver and renal function, tacrolimus dose and blood levels were analysed before and 12 weeks after the end of treatment.Results We identi...
Conclusions: Somatostatin concentrations were associated with CVP and CI in patients with HF. The pathophysiological mechanism may be related to congestion and/or hypoperfusion of the intestine. Somatostatin was an independent predictor of mortality in advanced HF.Cardiology
Conclusions: We demonstrate that R406W-desmin provokes its severe cardiotoxic potential by a novel pathomechanism, where the concurrent dual functional states of mutant desmin assembly complexes underlie the uncoupling of desmin filaments from intercalated discs and their structural disorganization. PMID: 33023321 [PubMed - as supplied by publisher]
CONCLUSION: Despite the complexity of the content and the emotionally sensitive nature of discussions around deceased organ donation, a well-planned strategy to involve patient partners is important, impactful, and central to the process. This suggests a broad interprofessional audience can engage with properly prepared and supported patient partners to strengthen and focus dialogue and outputs in the development of health policy in the donation and transplant sector. PMID: 33025456 [PubMed - as supplied by publisher]
ConclusionDespite the complexity of the content and the emotionally sensitive nature of discussions around deceased organ donation, a well-planned strategy to involve patient partners is important, impactful, and central to the process. This suggests a broad interprofessional audience can engage with properly prepared and supported patient partners to strengthen and focus dialogue and outputs in the development of health policy in the donation and transplant sector.
Peng DM, Koehl DA, Cantor RS, McMillan KN, Barnes AP, McConnell PI, Jordan J, Andersen ND, St Louis JD, Maeda K, Kirklin JK, Kindel SJ. Outcomes of children with congenital heart disease implanted with ventricular assist devices: An analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs). J Heart Lung Transplant 2019;38(4):420-30.
The total artificial heart (TAH) is a device that replaces the failing ventricles. There have been numerous TAHs designed over the last few decades, but the one with the largest patient experience is the SynCardia temporary TAH. The 50-mL and 70-mL sizes have been approved in the United States, Europe, and Canada as a bridge to transplantation. It is indicated in patients with severe biventricular failure or structural heart issues that preclude the use of a left ventricular assist device. The majority of the patients implanted are Interagency Registry for Mechanically Assisted Circulatory Support profile 1 or 2. The 1-yea...